Algal Bio Co., Ltd.

Based in Japan, Algal Bio Co. , Ltd. operates in the field of algal biotechnology, focusing on sustainable solutions to environmental challenges through innovative algal products. Algal Bio Co.

, Ltd. , founded in 2018 and headquartered in Kashiwa, Japan, specializes in algal research and development. The company has completed a total of 4 deals, with the latest being a Series B funding round on December 28, 2022, raising JPY 345 million. The CEO, Amane Kimura, works alongside founder Tsuyoshi Takeshita, who has a background in biotechnology and innovation.

Algal Bio has consistently focused on advancing its algal cultivation techniques to cater to diverse industries. Algal Bio Co. , Ltd. specializes in the research and development of algal-based solutions aimed at addressing critical societal challenges and enhancing environmental sustainability.

The company’s core offerings include functional algae cultivation and a range of applications derived from these products, which serve diverse industries such as food and beverage, cosmetics, and biofuels. Their innovative technologies focus on harnessing the nutritional potential of algae, which contributes to the creation of sustainable resources while aiding in carbon dioxide absorption through photosynthesis. Algal Bio targets B2B clients, including manufacturers and product developers, as well as direct consumers interested in sustainable living. Their products are particularly marketed in Asia-Pacific regions, with ongoing collaborations and partnerships enhancing their reach and impact.

Algal Bio generates revenue through a multifaceted transaction structure that includes partnerships, B2B sales, and direct consumer engagement. The company collaborates with various stakeholders, including major corporations in the food and beverage industry, to integrate its algal solutions into their products. Revenue is driven by contracts for algae cultivation services and the sale of finished algal-derived products, which may be offered in subscription models or as one-time purchases. Specific pricing plans for these services or products have not been disclosed, but clients benefit from tailored solutions that address their unique needs.

Through these strategies, Algal Bio aims to solidify its position in the clean technology sector while contributing to a more sustainable future. In December 2022, Algal Bio Co. , Ltd. raised JPY 345 million in Series B funding from investors including ITOCHU Corp, Joyo Industrial Research, Kiraboshi Capital, and Taiyo Nippon Sanso, alongside returning investors Abies Ventures and Kyoto University Innovation Capital.

The company plans to utilize these funds to enhance its biofoundry algae development platform and production capabilities. Future growth will focus on the launch of new products designed for additional market applications, with specific attention to expanding into the Asia-Pacific market by the end of 2024. Algal Bio aims to strengthen its operational capabilities to meet the demands of a growing customer base while continuing to address environmental challenges.